Pfizer announced a voluntary recall of another 4 lots of varenicline (Chantix) 0.5 mg/1 mg tablets to the consumer level due to the presence of a nitrosamine, N-nitroso-varenicline, above the established acceptable daily intake level.

After Pfizer announced in late June that it was halting worldwide distribution of varenicline (Chantix) after detecting elevated levels of nitrosamines in the drug, FDA came out to alert patients and health professionals about the voluntary recall.